Followers | 17 |
Posts | 936 |
Boards Moderated | 0 |
Alias Born | 04/26/2010 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, January 02, 2019 3:35:35 PM
I stand corrected. I should have written 'no evidence of BTD'.
I have doubts how complaint of omission to point out otherwise obvious fact would fare in legal actions. Reporting SOM incidence rates for intent to treat population plus only one out of possible two subgroups is like saying:" 5 minus 3 equals..." And leaving it to readers to figure out that it is 2 that follows. Seems to to OK as long as there is means for the reader to figure out what it was highlighted.
One enlightening example:
Yondelis was approved on 2016 to treat leiomyo- and liposarcomas (two most common soft tissue sarcomas, STS) based on statistically significant benefit in progression free survival (PFS). You can't find this tidbit in Yondelis FDA label or in the discussion section of published, peer reviewed article about the pivotal phase III clinical trial (comparator dacarbazine is generally considered borderline active in STS i.e. just above placebo):
Progression free survival in Liposarcoma overall Yondelis (trabectedin) vs dacarbazine
Yondelis: 3.0 months
Dacarbazine: 1.5 months
Progression free survival in Liposarcoma subgroups Yondelis (trabectedin) vs dacarbazine
Dedifferentiated
Yondelis: 2.2 months
Dacarbazine: 1.9 months
Myxoid / round cell
Yondelis: 5.6 months
Dacarbazine: 1.5 months
Pleomorphic
Yondelis: 1.5 months
Dacarbazine: 1.4 months
What do we see: Benefits Yondelis shows in liposarcoma are completely driven by Yondelis performance in ONE liposarcoma subgroup. This is not mentioned (no limiting clause for liposarcoma) in Yondelis FDA label and not in the discussion for Yodelis efficacy in the published, peer reviewed article about Yondelis phase III trial. So, how do I know about it: the above is from a table in Fig 2B of the trial article. That's it.
links:
Yondelis FDA label (the latest):
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207953s005lbl.pdf
Yondelis pivotal Phase III trial:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070559/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783302/
I could provide several other examples, but what would be point...
"I would rather have questions that can't be answered than answers that can't be questioned." Richard P. Feynman
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM